Tumori最新文献 - Book学术

Effects of uniportal 3D video-assisted thoracic surgery lobectomy on postoperative pain and immune function in patients with NSCLC. 单孔三维视频辅助胸外科肺叶切除术对非小细胞肺癌患者术后疼痛和免疫功能的影响。

IF 3.1 4区医学

Tumori Pub Date : 2025-10-01 Epub Date: 2025-07-28 DOI: 10.1177/03008916251351217

Shaoxin Li, Lina Yang, Zheng Huang

{"title":"Effects of uniportal 3D video-assisted thoracic surgery lobectomy on postoperative pain and immune function in patients with NSCLC.","authors":"Shaoxin Li, Lina Yang, Zheng Huang","doi":"10.1177/03008916251351217","DOIUrl":"10.1177/03008916251351217","url":null,"abstract":"Objective: This study focused on comparing the efficacy of uniportal three-dimensional (3D) video-assisted thoracic surgery (VATS) lobectomy and traditional two-dimensional (2D) VATS lobectomy in patients with non-small cell lung cancer (NSCLC).Methods: A retrospective analysis was performed on 84 NSCLC patients who underwent VATS lobectomy. Based on the type of thoracoscope used during surgery, patients were assigned to either the 3D group (n = 42), which received uniportal 3D VATS lobectomy, or the 2D group (n = 42), which underwent traditional 2D VATS lobectomy. Perioperative indicators, postoperative Visual Analog Scale (VAS) scores, pain-related factors [substance P (SP), norepinephrine (NE), and cortisol (COR)], immune function (CD3+, CD4+, and CD8+), lung function [forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and maximal voluntary ventilation (MVV)] were compared between the two groups.Results: The 3D group exhibited lower intraoperative blood loss, postoperative 24-hour drainage volume, drainage tube indwelling time, surgery duration, and hospitalization time compared to the 2D group (P < 0.05). Postoperatively, the 3D group reported lower VAS scores, lower levels of SP, NE, and COR, higher serum levels of CD3+ and CD4+, and higher FVC, FEV1, and MVV values compared to the 2D group (all P < 0.05).Conclusion: Uniportal 3D VATS lobectomy demonstrates clear advantages over traditional 2D VATS lobectomy for NSCLC patients by reducing perioperative pain, minimizing immune impairment, and preserving lung function.","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"433-441"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predicting severe toxicity after head-and-neck cancer RT: Validation of the synergist role of a biological marker and dosimetry. 预测头颈癌放疗后的严重毒性：生物标志物和剂量学的协同作用的验证。

IF 3.1 4区医学

Tumori Pub Date : 2025-10-01 Epub Date: 2025-09-15 DOI: 10.1177/03008916251367592

Sandrine Pereira, Tiziana Rancati, Nicola Alessandro Iacovelli, Mirlande Duclos, Elise Berthel, Sophie Deneuve, Anna Cavallo, Domenico Attilio Romanello, Francesco Fiorino, Riccardo Valdagni, Ester Orlandi

{"title":"Predicting severe toxicity after head-and-neck cancer RT: Validation of the synergist role of a biological marker and dosimetry.","authors":"Sandrine Pereira, Tiziana Rancati, Nicola Alessandro Iacovelli, Mirlande Duclos, Elise Berthel, Sophie Deneuve, Anna Cavallo, Domenico Attilio Romanello, Francesco Fiorino, Riccardo Valdagni, Ester Orlandi","doi":"10.1177/03008916251367592","DOIUrl":"10.1177/03008916251367592","url":null,"abstract":"Aim: To assess the value of biologically enriched Normal Tissue Complication Probability (NTCP) models integrating clinical, dosimetric, and biological markers, specifically the RadioDtect© assay based on phosphorylated ATM (Ataxia-Telangiectasia Mutated, pATM) quantification.Methods: We considered 67 patients with head-and-neck cancer receiving curative-intent radiotherapy. We developed logistic NTCP models for severe acute/late toxicities (grade ⩾3) using (i) the pATM-based RadioDtect test, (ii) clinical-dosimetric variables, and (iii) a combined model. Model performance was evaluated using AUC (Area Under the receiver operating characteristic Curve), calibration, and Net Reclassification Improvement (NRI), with internal validation via bootstrapping/permutation.Results: Acute and late toxicity occurred in 70% and 15% of patients. The RadioDtect test alone yielded moderate performance for late toxicity (AUC=0.65) and low discriminatory power for acute toxicity (AUC=0.57). Clinical-dosimetric models for acute toxicity demonstrated substantial predictive value (AUC=0.77), primarily driven by doses to the pharyngeal constrictor muscles and parotid glands. Integrating RadioDtect modestly improved discrimination for acute toxicity (AUC=0.82) but added no clinical utility (NRI=0%). Conversely, for late toxicity, doses showed poor association and discrimination for the occurrence of severe side effects. The biological refined NTCP model showed improved discrimination (AUC=0.76) and meaningful clinical utility (NRI=46.3%).Conclusions: The RadioDtect assay adds limited value for predicting acute toxicity in clinical settings entailing large volumes of organs at risk irradiated at high doses, but enhances NTCP models for late toxicity prediction.","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"420-432"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 3.1 4区医学

Tumori Pub Date : 2025-10-01 Epub Date: 2025-08-29 DOI: 10.1177/03008916251363754

Marco Stellato, Ernesto Zecca, Paola Bracchi, Alessandro Rametta, Melanie Claps, Valentina Guadalupi, Simone Rota, Giuseppe Fotia, Patrizia Giannatempo, Giuseppe Procopio, Elena Verzoni

{"title":"Medication-related jaw osteonecrosis in metastatic RCC treated with VEGFR-TKIs ± IO and bone agents: A real-world analysis.","authors":"Marco Stellato, Ernesto Zecca, Paola Bracchi, Alessandro Rametta, Melanie Claps, Valentina Guadalupi, Simone Rota, Giuseppe Fotia, Patrizia Giannatempo, Giuseppe Procopio, Elena Verzoni","doi":"10.1177/03008916251363754","DOIUrl":"10.1177/03008916251363754","url":null,"abstract":"Despite Immune-Oncology (IO) combinations, bone metastases (BM) remain a clinical challenge, occurring in ~30% of metastatic renal cell carcinoma (mRCC) patients and leading to skeletal-related events (SREs). Bone-targeted therapies (BTT), denosumab (Dmab) and zoledronic acid (ZOL AC), reduce SREs but are associated with a risk of Medication-Related Osteonecrosis of the Jaw (MRONJ), especially when combined with Vascular Endothelial Growth Factor Receptor - Tyrosine Kinase Inhibitors (VEGFR-TKIs). We retrospectively collected data from mRCC patients with BM who received IO alone or in combinations and VEGFR-TKIs concurrent or sequential with BTT from January 2013 to January 2025. We identified 104 mRCC patients who received BTT (Dmab: 86/104; ZOL AC: 18/104; switch: 4/104). MRONJ occurred in 12/104 (11.5%) patients, with a median BTT exposure of 13.8 months vs. 11.6 months in the overall cohort. At ONJ diagnosis, 10/12 patients were on VEGFR-TKI, one on IO (previously on pazopanib), and one off therapy (previously on tivozanib). Notably, patients on IO-IO or IO-TKI combinations (10) did not develop MRONJ. This study represents one of the largest real-world cohorts assessing MRONJ incidence in mRCC patients treated with VEGFR-TKIs and IO-combo with concomitant BTT. Our findings confirm an MRONJ rate consistent with prior reports (10-17%) of patients treated with TKIs monotherapy and BTT.","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"442-446"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144970770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of APOC1 levels and nutritional indices with clinicopathological features and prognostic value in patients with DLBCL. DLBCL患者APOC1水平及营养指标与临床病理特征及预后价值的关系

IF 3.1 4区医学

Tumori Pub Date : 2025-10-01 Epub Date: 2025-09-15 DOI: 10.1177/03008916251362015

Wei Wang, Qiqiang Long

{"title":"Association of APOC1 levels and nutritional indices with clinicopathological features and prognostic value in patients with DLBCL.","authors":"Wei Wang, Qiqiang Long","doi":"10.1177/03008916251362015","DOIUrl":"10.1177/03008916251362015","url":null,"abstract":"Objective: This study aims to unravel the relationship between apolipoprotein C1 (APOC1) levels, prognostic nutritional index (PNI), and clinicopathological characteristics in patients with diffuse large B-cell lymphoma (DLBCL) and their prognostic predictive value.Methods: This study retrospectively analyzed clinical data from 55 DLBCL patients and 50 healthy screening volunteers. APOC1 levels and the PNI were compared between groups, along with their association with DLBCL's clinicopathological features. Patients were stratified into favorable and poor prognosis groups based on the International Prognostic Index (IPI), with APOC1 and PNI compared between subgroups. Kaplan-Meier curves were used to analyze the impact of high and low expression levels of APOC1 and PNI on progression-free survival (PFS) and overall survival (OS) in DLBCL patients. Multivariate logistic regression identified risk factors for poor prognosis, while Receiver Operating Characteristic (ROC) curves assessed the predictive value of APOC1 and PNI for DLBCL outcomes.Results: DLBCL patients had higher APOC1 levels and lower PNI than controls. Patients with advanced-stage (III-IV) disease showed significantly increased APOC1 and decreased PNI compared to early-stage (I-II) cases. DLBCL patients with high APOC1 expression and low PNI showed left-shifted PFS and OS curves (P < 0.05). Both elevated APOC1 and reduced PNI were independent risk factors for poor prognosis, with Area Under the Curve (AUC)s of 0.836 and 0.779, respectively. Their combined predictive value improved, suggesting potential utility in prognosis assessment.Conclusion: APOC1 levels and PNI are significantly correlated with higher disease risk in DLBCL, and their combined evaluation may help improve risk assessment.","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"413-419"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives. 早期乳腺癌骨修饰剂的使用：AIOM指南的更新和观点。

IF 3.1 4区医学

Tumori Pub Date : 2025-10-01 Epub Date: 2025-09-15 DOI: 10.1177/03008916251367339

Alberto Zambelli, Riccardo Gerosa, Michela Cinquini, Massimo Di Maio, Federica Miglietta, Luca Arecco, Laura Biganzoli, Daniela Bernardi, Laura Cortesi, Lucia Del Mastro, Maria V Dieci, Jennifer Foglietta, Lucio Fortunato, Pierfrancesco Franco, Paola Mantellini, Caterina Marchiò, Bruno Meduri, Giovanni Micallo, Antonino Musolino, Andrea Salvetti, Daniele Santini, Gaetano Lanzetta, Deborah Cosentini, Francesco Bertoldo, Roberto Luigi Cazzato, Francesco Cellini, Vincenzo Denaro, Alberto Di Martino, Vittorio Fusco, Carlo Greco, Toni Ibrahim, Giulio Maccauro, Giulia DeFeo, Stefano Severi, Stefania Gori

{"title":"The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives.","authors":"Alberto Zambelli, Riccardo Gerosa, Michela Cinquini, Massimo Di Maio, Federica Miglietta, Luca Arecco, Laura Biganzoli, Daniela Bernardi, Laura Cortesi, Lucia Del Mastro, Maria V Dieci, Jennifer Foglietta, Lucio Fortunato, Pierfrancesco Franco, Paola Mantellini, Caterina Marchiò, Bruno Meduri, Giovanni Micallo, Antonino Musolino, Andrea Salvetti, Daniele Santini, Gaetano Lanzetta, Deborah Cosentini, Francesco Bertoldo, Roberto Luigi Cazzato, Francesco Cellini, Vincenzo Denaro, Alberto Di Martino, Vittorio Fusco, Carlo Greco, Toni Ibrahim, Giulio Maccauro, Giulia DeFeo, Stefano Severi, Stefania Gori","doi":"10.1177/03008916251367339","DOIUrl":"10.1177/03008916251367339","url":null,"abstract":"Breast cancer (BC) is the leading cause of cancer-related mortality among women, with early BC (EBC) comprising most cases. Advancements in neo(adjuvant) therapies have significantly improved outcomes, although they are often associated with cancer treatment-induced bone loss, which increases the risk of fractures and negatively impacts quality of life. Bone-modifying agents (BMAs), such as bisphosphonates and denosumab can mitigate this adverse effect. By reviewing and summarizing the most recent evidence published on BMAs use in EBC, an expert Italian Panel, composed of the authors of the Italian Association of Medical Oncology (AIOM) guidelines, offers an extended clinical interpretation and updated overview of key questions and recommendation, including the optimal timing of BMAs initiation, appropriate treatment duration, and the most effective agents for fracture risk reduction. Additionally, a critical and previously unaddressed topic is also discussed: BMAs impact on survival outcomes in EBC scenario. This paper offers practical insights into bone health management for EBC patients, explores the potential survival benefits offered by BMAs, and highlights differences among international guidelines regarding their recommended use.","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"366-378"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An indirect approach to identify the healthcare services for thyroid and melanoma cancer patients in Italy: Epicost-2 project. 确定意大利甲状腺和黑色素瘤癌症患者的医疗保健服务的间接方法：Epicost-2项目。

IF 3.1 4区医学

Tumori Pub Date : 2025-10-01 Epub Date: 2025-09-04 DOI: 10.1177/03008916251353109

Sandra Mallone, Andrea Tavilla, Tania Lopez, Daniela Pierannunzio, Luigino Dal Maso, Stefano Guzzinati, Ugo Fedeli, Alberto Gagliani, Alessandra Buja, Manuel Zorzi, Mario Fusco, Federica Toffolutti, Silvia Francisci

{"title":"An indirect approach to identify the healthcare services for thyroid and melanoma cancer patients in Italy: Epicost-2 project.","authors":"Sandra Mallone, Andrea Tavilla, Tania Lopez, Daniela Pierannunzio, Luigino Dal Maso, Stefano Guzzinati, Ugo Fedeli, Alberto Gagliani, Alessandra Buja, Manuel Zorzi, Mario Fusco, Federica Toffolutti, Silvia Francisci","doi":"10.1177/03008916251353109","DOIUrl":"10.1177/03008916251353109","url":null,"abstract":"Introduction: An indirect approach was applied to the case-study of thyroid cancer (TC) and melanoma of the skin (MS) in Italy to identify health services (HS) for cancer patients and to enable cost estimation.Materials and methods: Within the Epicost-2 project, a self-controlled crossover design analysed TC and MS 2018 prevalent cases from Italian cancer registries. Controls (1:1) were matched to cases 18-6 months prior to diagnosis; increases between cases and controls in potentially cancer-related HS claims (P⩽5%) were identified.Validation: Oncology and clinical experts validated cancer-related HS lists using statistical, clinical, and economic criteria.Results: The approach identified 202 and 333 cancer-related HS codes for TC and MS, respectively, aligned with clinical pathways.Discussion: The indirect approach reduced validation workload by 75% versus direct one.Conclusion: The approach identifies the costs of cancer care that could also be reproduced in other countries with consistent results, and the approach applied to other cancers.","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"400-412"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The e-BRAVE study: A prospective web-based cohort and biobank of women carriers of BRCA mutations. e-BRAVE研究：BRCA突变女性携带者的前瞻性网络队列和生物库。

IF 3.1 4区医学

Tumori Pub Date : 2025-10-01 Epub Date: 2025-08-09 DOI: 10.1177/03008916251353420

Andreina Oliverio, Carlotta Meli, Eleonora Bruno, Michela Bianchi, Giada Sassi, Elisabetta Venturelli, Ambra Cesareo, Claudio Pighini, Margherita Patruno, Maria Di Gennaro, Stefania Tommasi, Antonella Daniele, Silvia Schiavone, Letizia Galasso, Stefano Magno, Gianluca Franceschini, Alberta Ferrari, Robert Fruscio, Daniele Morelli, Claudia Chiodoni, Siranoush Manoukian, Patrizia Pasanisi

{"title":"The e-BRAVE study: A prospective web-based cohort and biobank of women carriers of BRCA mutations.","authors":"Andreina Oliverio, Carlotta Meli, Eleonora Bruno, Michela Bianchi, Giada Sassi, Elisabetta Venturelli, Ambra Cesareo, Claudio Pighini, Margherita Patruno, Maria Di Gennaro, Stefania Tommasi, Antonella Daniele, Silvia Schiavone, Letizia Galasso, Stefano Magno, Gianluca Franceschini, Alberta Ferrari, Robert Fruscio, Daniele Morelli, Claudia Chiodoni, Siranoush Manoukian, Patrizia Pasanisi","doi":"10.1177/03008916251353420","DOIUrl":"10.1177/03008916251353420","url":null,"abstract":"Background: Women carriers of BRCA1/2 mutations face a very high lifetime risk (penetrance) of developing breast and/or ovarian cancer. A sizeable proportion of carriers, however, does not develop cancer at all or develop it only late in life, thus suggesting a potential modulation of this risk. Epidemiological studies have suggested that other genetic (polymorphisms) and environmental factors (lifestyle) affect penetrance. However, data regarding these associations mainly come from retrospective case-control analyses and the results are likely to be distorted by bias.Aims: The e-BRAVE (Brca, ReseArch, Virtual, Education) study aims to create a web-based prospective cohort and biological bank of unaffected women carriers of BRCA1/2 mutations to investigate the role of polymorphisms and environmental factors, and their interaction, in the occurrence of primary BRCA-related cancers.Methods: An innovative digital platform (including a mobile App) will be used to empower the synergy between participants and researchers, supporting engagement with women, adherence to intervention plan, self-empowerment, flanked by activities tracking and monitoring.Results: Based on the incidence data in previous studies, we estimate to observe an overall incidence of ~3.7% year.Conclusion: The success of this study will ensure the definition of further predictive risk models and comprehensive recommendations aimed at improving management and health of BRCA women.","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"390-399"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144804966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delphi Study on the creation of a Committee of patients, caregivers, and representatives of patient associations. 德尔菲研究关于建立一个由患者、护理人员和患者协会代表组成的委员会。

IF 3.1 4区医学

Tumori Pub Date : 2025-10-01 Epub Date: 2025-08-30 DOI: 10.1177/03008916251346564

Laura Gangeri, Sara Alfieri, Valeria Anselmi, Bianca Scacciati, Elena Germini, Silvia Bernardelli, Cinzia Brunelli, Claudia Borreani

{"title":"Delphi Study on the creation of a Committee of patients, caregivers, and representatives of patient associations.","authors":"Laura Gangeri, Sara Alfieri, Valeria Anselmi, Bianca Scacciati, Elena Germini, Silvia Bernardelli, Cinzia Brunelli, Claudia Borreani","doi":"10.1177/03008916251346564","DOIUrl":"10.1177/03008916251346564","url":null,"abstract":"Background: As part of the improvement plan of the Organisation of European Cancer Institutes at the Fondazione IRCCS Istituto Nazionale dei Tumori of Milan (INT) a Committee composed of patients, caregivers, and representatives of patient associations has been established to actively participate in the planning and organization of both hospital services and research initiatives. The potential impact of implementation of the Committee could ensure a patient-centered care environment.Aim: To determine whether there is consensus among INT staff on key aspects of the Committee.Method: Selected INT staff (experts) were invited to participate in a Delphi study. Each expert was asked to rate their agreement on 13 statements and give a brief explanation for their answers. Only the statements that failed to reach an 80% consensus were reintroduced in the second round, following the same procedures.Results: Ninety experts responded to Round I (55.21% response rate). Eight statements reached the 80% consensus threshold, while five did not meet the predefined threshold and were therefore re-proposed in the second round. These statements concerned the Committee's role (advisory vs decision-making), the perceived value of the Committee in research (improvement vs no involvement), and participant compensation (voluntary vs paid). In Round II, 69 experts participated (79.31% response rate), but none of the reintroduced statements reached the required consensus threshold.Conclusion: Although a Committee is a topic of theoretical interest and aligns with respondents' values, the establishment of a Committee in INT is currently difficult to implement. Training and awareness initiatives are necessary, as requested by respondents.","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"379-389"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144970762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liquid biopsy in prostate cancer: A multidisciplinary expert consensus statement. 前列腺癌液体活检：多学科专家共识声明。

IF 3.1 4区医学

Tumori Pub Date : 2025-09-29 DOI: 10.1177/03008916251379317

Francesco Pepe, Davide Seminati, Gustavo Baldassarre, Gabriella Cirmena, Dario De Biase, Paola Francia di Celle, Elena Guerini Rocco, Elisa Melucci, Angelo Minucci, Lidia Moserle, Maria Iole Natalicchio, Giancarlo Pruneri, Maria Scatolini, Maria Cristina Sini, Stefania Tommasi, Simona Vatrano, Fabio Pagni, Umberto Malapelle

{"title":"Liquid biopsy in prostate cancer: A multidisciplinary expert consensus statement.","authors":"Francesco Pepe, Davide Seminati, Gustavo Baldassarre, Gabriella Cirmena, Dario De Biase, Paola Francia di Celle, Elena Guerini Rocco, Elisa Melucci, Angelo Minucci, Lidia Moserle, Maria Iole Natalicchio, Giancarlo Pruneri, Maria Scatolini, Maria Cristina Sini, Stefania Tommasi, Simona Vatrano, Fabio Pagni, Umberto Malapelle","doi":"10.1177/03008916251379317","DOIUrl":"https://doi.org/10.1177/03008916251379317","url":null,"abstract":"IntroductionBRCA1/2 testing via liquid biopsy has emerged as a critical, minimally invasive alternative to tissue sampling in metastatic castration-resistant prostate cancer (mCRPC), especially in the context of insufficient, inadequate, or unavailable tumor material.MethodsA multidisciplinary panel of 18 Italian experts from 16 leading academic and clinical institutions convened to develop consensus recommendations on BRCA1/2 testing via liquid biopsy. Through virtual and on-site meetings, technical gaps in pre-analytical, analytical, and post-analytical workflows were identified and addressed. Statements were approved by ⩾80% of panelists and reviewed to reflect both current evidence and expert practice.ResultsThe survey confirmed widespread implementation or imminent adoption of liquid biopsy testing across Italian centers, despite persistent challenges in standardizing sample collection, testing management, preservation, and reporting. Key technical insights included the importance of cfDNA-preserving tubes, optimal storage conditions, assay sensitivity (LoD <1.0%), and bioinformatic integration for detecting low-frequency variants. Next-generation sequencing was unanimously preferred, with BRCA1/2 coverage extended to coding and flanking regions. A harmonized synoptic report structure was proposed to enhance clinical interpretability and facilitate oncologic decision-making.ConclusionsDespite limitations in tissue availability, the integration of liquid biopsy into a diagnostic algorithm, endorsed by both AIOM and ESMO guidelines, enables broader access to BRCA1/2 stratification and supports timely PARP inhibitor therapy. This consensus aims to improve diagnostic consistency and clinical outcomes in the management of mCRPC across Italy.","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251379317"},"PeriodicalIF":3.1,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sequential therapy of metastatic urothelial cancer with monomethyl auristatin E (MMAE)-containing antibody-drug conjugates for different targets. 转移性尿路上皮癌序贯治疗不同靶点含单甲耳素E （MMAE）的抗体-药物偶联物

IF 3.1 4区医学

Tumori Pub Date : 2025-09-29 DOI: 10.1177/03008916251362021

Jiaping Yang, Zhenxia Ma, Weiqin Sun, Mingjuan Sun, Sheng Zhang

引用次数: 0